Significant Association Between Low Baseline Neutrophil-to-Lymphocyte Ratio and Improved Progression-free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab-Paclitaxel

摘要

Both eribulin and nab-paclitaxel are widely used and effective chemotherapy agents for metastatic breast cancer; however, their predictive factors remain unknown. The usefulness of the neutrophil-to-lymphocyte ratio (NLR) in terms of treatment efficacy was investigated. We observed that a low NLR at baseline might be a significant indicator of improved outcomes for patients treated with eribulin but not with nab-paclitaxel.